Controlled group allocation has quietly become one of the hardest parts of claiming the R&D credit. The finalized Form 6765 instructions clarify how member entities should report QRE totals, yet a disconnect still exists between the instructions and the actual computation mechanics for some controlled groups. If your organization spans multiple subsidiaries, joint ventures, or recently acquired entities, that disconnect creates real filing risk.
Why Controlled Groups Complicate Everything
A controlled group must compute the credit as if all members were a single taxpayer, then allocate the group credit among members based on each entity’s share of qualified research expenses. That sounds straightforward on paper, but it gets messy in practice, especially when member entities use different fiscal years, run different ERP systems, or apply inconsistent definitions of what counts as a business component.
Fortune 100 organizations rarely operate as one clean legal entity performing research. Most operate as a collection of subsidiaries, each with its own finance team, its own project tracking conventions, and often its own history of how it claimed the credit before an acquisition folded it into the larger group. Section G’s business-component reporting requirement forces all of that inconsistency into view at the same time, on the same return.
The Allocation Trap Most Teams Fall Into
Many groups allocate the credit proportionally based on each member’s QRE share, then stop there. That approach misses a step that matters just as much: verifying that each member’s underlying business-component detail actually supports the allocation it claims. If Subsidiary A claims 40 percent of group QREs but can’t produce component-level documentation for that share, the allocation looks defensible on paper and falls apart the moment an examiner asks for support.
Our 6765 Business Component Solution exists because allocation math and documentation quality have to move together. A correct allocation percentage means little if the supporting narrative behind it doesn’t hold up at the entity level.
Where Recent Acquisitions Create Exposure
If your organization acquired a company in the past several years, take a closer look at how that entity’s research history entered your group filing. Newly acquired entities often bring inconsistent R&D credit histories with them: different interpretations of the four-part test, different treatment of funded research, and documentation standards that don’t match what the rest of your group uses. Folding that entity into your controlled group filing without reconciling those differences creates a weak link, and it’s usually the first place an examiner will look.
This is exactly the kind of gap that shows up during enforcement. Our review of Smith v. Commissioner and its clarification of funded research rules shows how quickly funded research questions can unravel a claim when documentation doesn’t match the legal standard. Controlled groups that absorbed research programs through mergers and acquisitions face this risk more than most, simply because the acquired entity’s records rarely follow the acquiring company’s conventions from day one.
Building a Defensible Controlled Group Process
Start with an entity-by-entity review of your current documentation standards. Look for consistency gaps, not just missing paperwork. Does every member entity define “business component” the same way? Does every entity track supervision and support wages with the same level of rigor, or does that discipline vary depending on which finance team handles it?
From there, formalize your allocation methodology in writing, and update it whenever your group structure changes. A controlled group that divests a business unit or acquires another mid-year needs a documented approach for how that shift affects the group’s QRE allocation. Building that calculation from scratch during filing season, under time pressure, tends to produce weaker support than a methodology worked out and documented well in advance.
Finally, take an honest look at whether your in-house team has the time to manage this across every entity, every year. Many organizations that built strong in-house credit programs after moving away from a Big 4 provider find controlled group reconciliation is the piece that strains internal resources the most. Our work helping teams move from Big 4 to in-house consistently surfaces controlled group allocation as the area where outside support earns its keep, mostly because the entity-level detail work takes far more hours than most teams budget for it.
Where This Leaves Controlled Groups in 2026
Controlled group reporting under the new Form 6765 rewards organizations that already standardized their documentation across entities, and it penalizes organizations that let each subsidiary manage its own process on its own timeline. If your group hasn’t run a cross-entity consistency check in the past year, this is the year to do it, before Section G makes every inconsistency visible to an examiner at once, all in the same request.
The credit’s value hasn’t changed for controlled groups. What has changed is how much detail the IRS can see, and how quickly one weak entity-level claim can put the whole group’s filing under closer review than it would otherwise get.
A Starting Point for Your Own Group
Pull a list of every entity in your controlled group and ask each finance lead the same three questions: how do you define a business component, how do you allocate supervision and support wages, and how far back does your documentation go. The answers will vary more than you expect, and that variance is exactly what Section G will expose if you don’t address it first. If that exercise turns up more inconsistency than your team can untangle alone, reach out and we’ll walk through it together.
September 24, 2026
2:00 pm EST
The 6765 Business Component Solution
Full Outsource
Big 4 to In-House
Reverse Audit
State Tax Incentives
Tax Controversy
R&D Staffing Services
174 Assistance